Does neuronal loss in Parkinson's disease involve programmed cell death?

BioEssays

Volumn 23, Issue 7, 2001, Pages 640-646

  Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE;

ANIMAL; APOPTOSIS; BRAIN; CULTURE TECHNIQUE; CYTOLOGY; DISEASE MODEL; HUMAN; METABOLISM; MITOCHONDRION; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; REVIEW;

ANIMALS; APOPTOSIS; BRAIN; CELL CULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; GLUTATHIONE; HUMANS; MITOCHONDRIA; NEURONS; PARKINSON DISEASE;

ANIMALIA; PARKINSONIA;

EID: 0034926105     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.1089     Document Type: Review

References (66)

1. Is levodopa toxic?
2. Induction of apoptosis in catecholaminergic PC12 cells by L-dopa: Implications for Parkinson's disease
3. Apoptosis in neurological disease
4. Programmed cell death: Does it play a role in Parkinson's disease?
5. Caspases - Controlling intracellular signals by protease zymogen activation
6. Controlling cell death
7. Double identity for proteins of the Bcl-2 family
8. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c.
9. Histochemical detection of apoptosis in Parkinson's disease
10. Apoptosis and autophagy in in nigral neurons of patients with Parkinson's disease
11. Apoptotic-like changes in Lewy body associated disorders and normal aging in substantia nigral neurons
12. Is differential regulation of mitochondrial transcription in Parkinson's disease related to apoptosis?
13. DNA fragmentation in human substantia nigra: Apoptosis or perimortem effect?
14. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
15. Apoptosis in neurodegenerative diseases: The role of mitochondria
16. On the question of apoptosis in the parkinsonian substantia nigra
17. Glial pathology but absence of apoptostic nigral neurons in long-standing Parkinson's disease
18. Cell death and apoptosis regulating proteins in Parkinson's disease-a cautionary note
19. Cell death mechanisms in Parkinson's disease
20. Contribution of somal Lewy bodies to neuronal death
21. Neuropharmacologic aspects of apoptosis: Significance for neurodegenerative disease
22. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease
23. Bcl-2 protein is increased in the brain from parkinsonian patients
24. Upregulation of the anti-apoptotic protein bcl-2 may be an early event in the neurodegeneration: Studies on Parkinson's and incidental Lewy body disease
25. Expression of bcl-2 in adult human brain regions with special reference to neurodegenerative disease
26. In situ detection of apoptotic nuclei in the substantia nigra pars compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydrophenylpyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange
27. Poly(ADP-robise) polymerase inhibitors protects against MPTP-induced depletion in striatal dopamine and cortical noradrenaline in C57BI/6 mice
28. Increase in bax expression in substanita nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice
29. Transgenic mice expressing human bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-1,2,3,6-tetrahydropyridine neurotoxicity
30. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity is attenuated in mice overexpressing bcl-2
31. Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated mice
32. 2-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo
33. Opposing effects of ERK and JNK-38 MAP kinases on apoptosis
34. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attentuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo
35. Early developmental destruction of terminals in the striatal target induces apoptosis in dopaminergic neurons of the substantia nigra
36. 6-hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra
37. 6-hydroxydopamine lesions of the rat substantia nigra: Time course and morphology of cell death
38. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: Relevance to Parkinson's disease
39. 1-methyl-4-phenylpyridine (MPP+) induced death in PC12 cells: Inhibitory effects of several drugs
40. Two distinct mechanisms are involved in 6-hydroxydopamine-and MPP+-induced dopaminergic neuronal cell death: Role of caspases, ROS, and JNK
41. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons
42. Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins
43. Characterization and time course of MPP+-induced apoptosis in human SH-SY5Y neuroblastoma cells
44. Neurotoxin induced cell death in neuronal PC12 cells is mediated by induction of apoptosis
45. Involvement of caspase-like proteinases in apoptosis of neuronal PC12 cells and primary cultured microglia induced by 6-hydroxydopamine
46. P53 and bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells
47. Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson's disease
48. Overexpression of HA-BAX but not Bcl-2 or Bcl-xL attenuates 6-hydroxydopamine induced neuronal apoptosis
49. Prevention of dopamine-induced cell death by thiol antioxidants-possible implications for treatment of Parkinson's disease
50. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway
51. MPTP-induced necrosis and apoptosis is a dose-dependent event
52. Mitochondrial dysfunction in Parkinson's disease
53. Mitochondrial complex I deficiency in Parkinson's disease
54. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors
55. Mitochondria in neurodegenerative apoptosis: An opportunity for therapy?
56. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients
57. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease
58. Dithiocarbamates and the redox regulation of cell death
59. Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neural cells: Relevance to Parkinson's disease
60. Direct evidence for glutathione as mediator of apoptosis in neural cells
61. Glutathione deficiency leads to mitochondrial damage in brain
62. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease
63. Shift of the cellular oxidation-reduction potential in neural cells expressing bcl-2
64. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease